International Trade Commission Briefing 2026-10-16
Estimated reading time: 5 minutes
1. N-Cyclohexylbenzothiazole-2-Sulfenamide From China; Scheduling of the Final Phase of Countervailing Duty and Antidumping Duty Investigations
Sub: International Trade Commission
Content: The Commission hereby gives notice of the scheduling of the final phase of antidumping and countervailing duty investigation Nos. 701-TA-797 and 731-TA-1793 (Final) pursuant to the Tariff Act of 1930 to determine whether an industry in the United States is materially injured or threatened with material injury, or the establishment of an industry in the United States is materially retarded, by reason of imports of n-cyclohexylbenzothiazole-2-sulfenamide (CBS) from China, provided for in subheading 2934.20.80 of the Harmonized Tariff Schedule of the United States, preliminarily determined by the Department of Commerce ("Commerce") to be subsidized and alleged to be sold at less-than-fair-value. Commerce's preliminary determination with respect to CBS from China, alleged to be sold in the United States at less- than-fair-value, is pending.
2. Certain Semiconductor Devices, Products Containing Same, and Components Thereof; Notice of Commission Determination Not To Review an Initial Determination To Amend the Complaint and Notice of Investigation
Sub: International Trade Commission
Content: Notice is hereby given that the U.S. International Trade Commission has determined not to review an initial determination ("ID") (Order No. 8) of the presiding administrative law judge ("ALJ") granting complainant GlobalFoundries U.S. Inc.'s motion to amend the complaint and notice of investigation ("NOI") to assert dependent claims 8-12 and 19 of U.S. Patent No. 8,507,983 ("the '983 patent").
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
